Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Neosine Forte
The advertisement is misleading, suggesting that Neosine Forte tablets are effective against COVID-19 coronavirus infections, can be used in prevention and treatment of these infections, and unethically exploits fear associated with the epidemic situation. Potential effects: lack of effective treatment, delay of appropriate therapy, worsening of the disease.
Megalia
Failure to meet quality requirements for this batch was found regarding the microbiological purity parameter, which may indicate the presence of microorganisms in the product and a potential risk to patients' health. Potential effects: infections, adverse reactions, lack of treatment efficacy.
Esmya
A case of severe liver injury in a patient using ulipristal acetate 5 mg was identified, requiring liver transplantation; there is a real, significant probability of serious harm to health or life. Potential effects: severe liver damage, liver failure, life-threatening complications.
Ulipristal Acetate Gedeon Richter
The PRAC Committee recorded a new case of severe liver injury after the use of ulipristal 5 mg, which required a liver transplant; the existing risk minimisation measures were deemed insufficient. Potential effects: severe liver damage, liver failure, life-threatening condition.
Ulimyo
Severe liver injury was identified after use of the product, in one case requiring a liver transplant, indicating an unfavorable benefit-risk balance. Potential effects: severe liver damage, life‑threatening complications, lack of treatment safety.
Ulipristal Alvogen
A new case of severe liver injury requiring transplantation and a justified suspicion that the medicine causes serious adverse reactions, altering the benefit–risk balance and creating a real, high probability of risk to patients’ health or life. Potential effects: severe liver damage, life‑threatening complications.
Reseligo
A result out of specification was found for active substance content, indicating a quality defect that may lead to improper drug action. Potential effects: treatment failure or adverse reactions.
Saridon
It was found that the packaging materials do not meet requirements – some packs of the product are labeled in Hungarian, which may lead to misunderstanding of information about the medicine. Potential effects: incorrect use of the medicine, lack of efficacy, complications.
Sulfarinol
Out-of-specification results were found in tested archival samples for the listed Sulfarinol batches regarding the parameter naphazoline nitrate impurity – another single impurity. Potential effects: possible adverse reactions, lack of efficacy or other complications related to uncontrolled impurity.
Sulfarinol
Out-of-specification results were found in archival samples for the parameter naphazoline nitrate contamination – another single impurity, which creates a potential risk to patients’ health or life. Potential effects: mucosal irritation, systemic adverse effects, lack of therapeutic efficacy.
Tetmodis
Out-of-specification results were found for active substance content in batch T1702PL of Tetmodis (Tetrabenazine), which may mean an inappropriate dose for the patient. Potential effects: lack of efficacy or increased adverse effects.
Sulfarinol
Out-of-specification results were found in archival samples of Sulfarinol batches for the parameter “naphazoline nitrate contamination – other single impurity”, indicating a quality defect of the product. Potential effects: reduced treatment efficacy and possible adverse reactions of unpredictable intensity.
Flegafortan
It was found that the patient leaflet regarding recommended dosing was inconsistent with the Summary of Product Characteristics, which could lead to incorrect use of the product and overdose manifested by unintended increased volume of bronchial secretions. Potential effects: overdose, increased bronchial secretion, respiratory complications.
Mitomycin Accord
A quality defect was found consisting in the inability to dissolve the powder, which may prevent preparation of a correct injection/infusion solution and result in failure to administer the proper drug dose. Potential effects: lack of treatment efficacy, complications of oncological therapy.
Flegafortan
The patient leaflet regarding recommended dosing was inconsistent with the approved Summary of Product Characteristics, which could lead to incorrect use and overdose manifested by increased volume of bronchial secretions. Potential effects: overdose, worsening cough and adverse drug reactions.
Sulfarinol
The tested retention samples showed out-of-specification results for the parameter “naphazoline nitrate contamination – other single impurity”, which may indicate the presence of an undesirable chemical compound in the product. Potential effects: possible adverse effects, irritation, lack of efficacy or other unpredictable reactions.
Espumisan 100 mg/ml
In several packs of the product, information leaflets for the medicinal product Zentel were detected instead of the correct Espumisan leaflet. Potential effects: incorrect use of the medicine, risk of improper dosing or lack of treatment efficacy.
Lecalpin
The defect was reported due to the detection of Lecalpin 10 mg blisters, batch 268018, inside outer cartons intended for Lecalpin 20 mg. Potential effects: possible intake of an incorrect dose and reduced treatment efficacy.
Spasmolina
The non-compliance consisted in not placing on the packaging of prescription medicinal products the safety features: a unique identifier and an anti-tampering device. Potential effects: falsification of the medicine, misidentification, risk of lack of appropriate treatment.
Kalium effervescens bezcukrowy
Lack of a unique identifier and an anti-tampering device on the packaging of prescription-only products, which could hinder verification of authenticity and detection of package tampering. Potential effects: risk of falsified medicine or interference with the packaging, possible lack of efficacy or adverse effects.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.